Holen Sie sich die Stockscreener-App
3.05
0.66%
0.02
Handel nachbörslich:
3.08
0.03
+0.98%
Schlusskurs vom Vortag:
$3.03
Offen:
$3.09
24-Stunden-Volumen:
235.69K
Relative Volume:
0.11
Marktkapitalisierung:
$9.83M
Einnahmen:
$12.99M
Nettoeinkommen (Verlust:
$-23.72M
KGV:
-0.0314
EPS:
-97.2514
Netto-Cashflow:
$-23.28M
1W Leistung:
+3.39%
1M Leistung:
-26.86%
6M Leistung:
-96.61%
1J Leistung:
-99.06%
1-Tages-Spanne:
$3.0114
$3.18
1-Wochen-Bereich:
$2.86
$3.18
52-Wochen-Spanne:
$2.81
$381.10
Aptevo Therapeutics Inc Stock (APVO) Company Profile
Firmenname
Aptevo Therapeutics Inc
Sektor
Branche
Telefon
206-838-0500
Adresse
2401 4TH AVE., SEATTLE, WA
Vergleichen Sie APVO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
APVO
Aptevo Therapeutics Inc
|
3.05 | 9.51M | 12.99M | -23.72M | -23.28M | -97.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Aptevo Therapeutics Inc Stock (APVO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2018-11-05 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-10-05 | Fortgesetzt | Piper Jaffray | Overweight |
Aptevo Therapeutics Inc Aktie (APVO) Neueste Nachrichten
What drives Aptevo Therapeutics Inc. stock priceMarket-beating performance - jammulinksnews.com
Is Aptevo Therapeutics Inc. a good long term investmentOutstanding investment returns - jammulinksnews.com
Aptevo Therapeutics Inc. Stock Analysis and ForecastFastest-growing stock picks - jammulinksnews.com
What analysts say about Aptevo Therapeutics Inc. stockAccelerated profit realization - jammulinksnews.com
Aptevo Meets Nasdaq $2.5M Equity Requirement - MSN
What makes Aptevo Therapeutics Inc. stock price move sharplyFree Access to Community - Newser
Why Aptevo Therapeutics Inc. stock attracts strong analyst attentionFree Elite Traders Group - Newser
How Aptevo Therapeutics Inc. stock performs during market volatility2x 3x 5x Pick Alert - Newser
10 Best Get Rich Quick Stocks to Buy Now - Insider Monkey
Aptevo regains Nasdaq compliance following $15.9 million equity raise By Investing.com - Investing.com India
Aptevo Therapeutics Regains Nasdaq Compliance with Equity Raise - TipRanks
Aptevo regains Nasdaq compliance following $15.9 million equity raise - Investing.com
Aptevo Therapeutics Raises $15.9M to Meet Nasdaq Compliance - TipRanks
Aptevo (APVO) appoints Baker Tilly as auditor after Moss Adams merger - Stock Titan
Aptevo Therapeutics' 18.7% Plunge: What Drives a Volatile Day Without News? - AInvest
Benzinga Bulls And Bears: Circle, Sunrun, JetBlue — And Mideast Has Markets Nervous - Benzinga
Aptevo (APVO) appoints Baker Tilly as auditor after Moss Adams merger | C SEC FilingForm 424B2 - Stock Titan
Aptevo Therapeutics Surges 82% Amid No Fundamental News—What’s Driving the Spike? - AInvest
Top Small Cap Stocks Worth WatchingJune 18th - MarketBeat
Crude Oil Moves Higher; US Weekly Jobless Claims Decline - Benzinga
Aptevo Therapeutics raises $8 million in registered direct offering - Investing.com Australia
Dow Surges 150 Points; Korn Ferry Earnings Top Views - Benzinga
Aptevo Therapeutics (APVO) Secures $8M Through Direct Offering - GuruFocus
Aptevo Therapeutics announces $8M at-the-market equity offering with warrants; shares more than double - MSN
Aptevo Therapeutics raises $8 million in registered direct offering By Investing.com - Investing.com India
Why Is Micro-Cap Aptevo Stock Trading Higher On Wednesday?Aptevo Therapeutics (NASDAQ:APVO) - Benzinga
Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules | APVO Stock News - GuruFocus
An early stage 85% remissions rate in AML drives Aptevo’s stock surge - BioWorld MedTech
Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules - ACCESS Newswire
Aptevo Secures $8M Funding: Biotech Company Accelerates Cancer Drug Development Pipeline - Stock Titan
Aptevo Therapeutics stock soars after impressive AML treatment results - Investing.com
Aptevo Therapeutics stock soars after impressive AML treatment results By Investing.com - Investing.com Canada
Why did Aptevo Therapeutics Shares Skyrocket in Premarket Trading Today? - Tokenist
Aptevo Therapeutics Skyrockets on Game-Changing AML Drug News - RagingBull
Aptevo reports 85% remission rate in frontline AML trial By Investing.com - Investing.com Nigeria
Aptevo Therapeutics (APVO) Shows Promising Results in RAINIER Tr - GuruFocus
Aptevo Says Its Mipletamig Therapy Achieves 85% Remission Rate in Leukemia Patients; Shares Soar Pre-Bell - MarketScreener
Aptevo Therapeutics (APVO) Shows Promising Results in AML Trial - GuruFocus
Aptevo Therapeutics announces new clinical data from RAINIER trial - TipRanks
Aptevo announces clinical data from ongoing Phase 1b/2 RAINIER trial - TipRanks
Breakthrough AML Drug Achieves 85% Remission Rate: New Hope for Previously Untreatable Patients - Stock Titan
Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML | APVO Stock News - GuruFocus
Aptevo Therapeutics Signs Equity Purchase Agreement - TipRanks
APVO Secures Roth Capital Partners as Exclusive Placement Agent - GuruFocus
Short Interest in Aptevo Therapeutics Inc. (NASDAQ:APVO) Decreases By 55.0% - Defense World
Aptevo Stock Rises On $2.1M Registered Direct Offering, Warrant Sale: Retail Sentiment Touches Year-High - MSN
Aptevo Participating in the BIO International Convention | APVO Stock News - GuruFocus
Aptevo Sends Business Development Team to BIO 2025: Major Partnership Opportunities Ahead - Stock Titan
Finanzdaten der Aptevo Therapeutics Inc-Aktie (APVO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):